Literature DB >> 18417099

Daytime functioning in older patients suffering from chronic insomnia: treatment outcome in a randomized controlled trial comparing CBT with Zopiclone.

Siri Omvik1, Børge Sivertsen, Ståle Pallesen, Bjørn Bjorvatn, Odd E Havik, Inger Hilde Nordhus.   

Abstract

The paper presents data from a randomized controlled trial comparing treatment effects of cognitive behavioural therapy (CBT), hypnotic treatment (Zopiclone), and placebo in a sample of insomnia patients. Data from the same trial have already demonstrated that CBT was more efficient in improving sleep than Zopiclone. The novel outcomes that are reported here concern daytime functioning. Forty-six older patients (age >or= 55) qualifying for a diagnosis of primary insomnia were recruited to participate. Assessments were completed at baseline, post-treatment, and at a 6-months follow-up, and measures of worry, anxiety, depression, interpersonal relationships, subjective alertness, vigilance, and quality of life were used. The participants in both treatment conditions scored within the normal range on the outcome measures at baseline with the exception of reporting less alertness, relative to a group of good sleepers. One interaction effect indicated that subjective alertness improved more in the Zopiclone group than the CBT group from baseline to post-treatment, and another that CBT was more effective than Zopiclone in reducing trait anxiety from baseline to follow-up. It was concluded that the treatments yielded only minor effects on the measures of daytime functioning, and that none of them was clearly superior to the other.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18417099     DOI: 10.1016/j.brat.2008.02.013

Source DB:  PubMed          Journal:  Behav Res Ther        ISSN: 0005-7967


  9 in total

1.  Towards an improved neuropsychology of poor sleep?

Authors:  Colin A Espie; Simon D Kyle
Journal:  Sleep       Date:  2008-05       Impact factor: 5.849

2.  Treating primary insomnia: clinical effectiveness and predictors of outcomes on sleep, daytime function and health-related quality of life.

Authors:  L Van Houdenhove; B Buyse; L Gabriëls; O Van den Bergh
Journal:  J Clin Psychol Med Settings       Date:  2011-09

Review 3.  Insomnia in Elderly Patients: Recommendations for Pharmacological Management.

Authors:  Vivien C Abad; Christian Guilleminault
Journal:  Drugs Aging       Date:  2018-09       Impact factor: 3.923

Review 4.  Zolpidem: Efficacy and Side Effects for Insomnia.

Authors:  Amber N Edinoff; Natalie Wu; Yahya T Ghaffar; Rosemary Prejean; Rachel Gremillion; Mark Cogburn; Azem A Chami; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2021-06-18

5.  Sleep and sleep disorders in chronic users of zopiclone and drug-free insomniacs.

Authors:  Børge Sivertsen; Siri Omvik; Ståle Pallesen; Inger Hilde Nordhus; Bjørn Bjorvatn
Journal:  J Clin Sleep Med       Date:  2009-08-15       Impact factor: 4.062

Review 6.  Does effective management of sleep disorders reduce depressive symptoms and the risk of depression?

Authors:  Dieter Riemann
Journal:  Drugs       Date:  2009       Impact factor: 9.546

7.  Effect of Digital Cognitive Behavioral Therapy for Insomnia on Health, Psychological Well-being, and Sleep-Related Quality of Life: A Randomized Clinical Trial.

Authors:  Colin A Espie; Richard Emsley; Simon D Kyle; Christopher Gordon; Christopher L Drake; A Niroshan Siriwardena; John Cape; Jason C Ong; Bryony Sheaves; Russell Foster; Daniel Freeman; Joan Costa-Font; Antonia Marsden; Annemarie I Luik
Journal:  JAMA Psychiatry       Date:  2019-01-01       Impact factor: 21.596

Review 8.  Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review.

Authors:  Matthew D Mitchell; Philip Gehrman; Michael Perlis; Craig A Umscheid
Journal:  BMC Fam Pract       Date:  2012-05-25       Impact factor: 2.497

9.  Effects of digital Cognitive Behavioural Therapy for Insomnia on cognitive function: study protocol for a randomised controlled trial.

Authors:  Simon D Kyle; Madeleine E D Hurry; Richard Emsley; Annemarie I Luik; Ximena Omlin; Kai Spiegelhalder; Colin A Espie; Claire E Sexton
Journal:  Trials       Date:  2017-06-17       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.